Clinical Trial Results:
Vitamin D supplementation and male infertility: a randomized double blinded clinical trial
Summary
|
|
EudraCT number |
2010-024588-42 |
Trial protocol |
DK |
Global end of trial date |
26 Jan 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Mar 2022
|
First version publication date |
29 Mar 2022
|
Other versions |
|
Summary report(s) |
Final publication |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
2010124801
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Dept. of Growth and Reproduction, Rigshospitalet
|
||
Sponsor organisation address |
Blegdamsvej 9, København Ø, Denmark, 2100
|
||
Public contact |
MD, PhD, Niels Jørgensen , Dept. of Growth and Reproduction , blombergjensen@gmail.com
|
||
Scientific contact |
MD, PhD, Niels Jørgensen , Dept. of Growth and Reproduction , +45 35459592, blombergjensen@gmail.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
25 Jul 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
29 Aug 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
26 Jan 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To investigate whether vitamin D supplementation to vitamin D deficient or insufficient men improves semen quality and male fertility
|
||
Protection of trial subjects |
During intervention period trial subjects had the opportunity to contact the outpatient clinic, with questions or symptoms.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
10 Jan 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 307
|
||
Worldwide total number of subjects |
307
|
||
EEA total number of subjects |
307
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
307
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
- | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
A total of 1427 men were referred with male infertility and screened . Of these, 330 infertile men formed the study cohort: 1002 men did not meet all inclusion criteria or met an exclusion criterion, and 95 men were eligible but did not wish to participate. The main reasons for exclusion were high vitamin D status, comorbidities or azoospermia. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Monitor | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Vitamin D | |||||||||||||||
Arm description |
cholecalciferol | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Cholecalciferol
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Infertile men were randomly assigned 1:1 to either placebo or an initial oral dose of 300,000 IU of cholecalciferol dissolved in oil, followed by receipt of tablets consisting of cholecalciferol 1400 IU and calcium 500 mg once daily for 150 days (Pfizer, Copenhagen, Denmark).
|
|||||||||||||||
Arm title
|
placebo | |||||||||||||||
Arm description |
Placebo tbl | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
calcium 500 mg x 1 daily
|
|||||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Vitamin D
|
||
Reporting group description |
cholecalciferol | ||
Reporting group title |
placebo
|
||
Reporting group description |
Placebo tbl |
|
|||||||||||||
End point title |
Differences in semen quality | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
150 days
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
BIOSTATISTICAL ANALYSIS | ||||||||||||
Comparison groups |
Vitamin D v placebo
|
||||||||||||
Number of subjects included in analysis |
269
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Median difference (final values) | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||
Timeframe for reporting adverse events |
January 2011 to January 2015
|
||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||
Dictionary name |
GCP | ||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||
Reporting group title |
pancreatitis
|
||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: please see attachment for details |
|||||||||||||||||||||
|
|||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/29126319 |